|

Fianlimab Clinical Trials

10 actively recruiting trials across 9 locations

▼ -1 trial since June 2026

Also known as: Anti-LAG-3 MoAb, Anti-LAG-3 MoAb REGN3767, REGN 3767, REGN3767, WHO 11182

Pipeline

Phase 1: 1Phase 2: 8Phase 3: 1

Top Sponsors

  • Regeneron Pharmaceuticals3
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins2
  • Montefiore Medical Center1
  • Memorial Sloan Kettering Cancer Center1
  • Mayo Clinic1

Indications

  • Cancer10
  • Colorectal Cancer2
  • Lung Cancer2
  • Advanced Renal Cell Carcinoma (aRCC)1
  • Clear Cell Renal Cell Carcinoma (ccRCC)1

Baltimore, Maryland2 trials

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Phase 2
Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

Johns Hopkins SKCCC

Phase 2

Birmingham, Alabama1 trial

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

The University of Alabama at Birmingham

Phase 2

Chandler, Arizona1 trial

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Ironwood Cancer & Research Centers

Phase 3

La Jolla, California1 trial

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Scripps Clinic Torrey Pines

Phase 1

Rochester, Minnesota1 trial

Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer

Mayo Clinic in Rochester

Phase 2

Basking Ridge, New Jersey1 trial

A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activites)

Phase 2

New York, New York1 trial

Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

Columbia University Irving Medical Center/ New York Presbyterian Hospital

Phase 2

The Bronx, New York1 trial

Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

Montefiore Einstein Comprehensive Cancer Center (MECCC)

Phase 2

Nashville, Tennessee1 trial

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Vanderbilt-Ingram Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.